Study on Using ILARIS® to Treat Proliferative Diabetic Retinopathy
May 15, 2012
The Department of Ophthalmology at Triemli Hospital in Zurich is recruiting recipients for a study evaluating the efficacy and safety of Canakinumab (ILARIS®) to treat proliferative diabetic retinopathy secondary to type 1 and 2 diabetes.
Ten subjects will be enrolled to receive 150 mg Canakinumab (ILARIS®) by subcutaneous injection. Beginning on day 0, each subject will receive a subcutaneous injection of study drug every 8 weeks for 16 weeks, a total of 3 injections. All subjects will undergo regular follow-up assessments every 8 weeks through 24 weeks. Fluorescein angiography (FA) will be repeated every 8 weeks. The primary outcome being sought is the regression of retinal neovascularizations by week 24.
Key secondary outcomes sought include regression of diabetic macular edema, and change in best-corrected visual acuity.
Click here to learn more about this study.
Jump down to form below to submit your own comments